CN116676385A - Application of LINC02096 in serving as marker for predicting esophageal cancer immunotherapy effect and prognosis and treatment target - Google Patents
Application of LINC02096 in serving as marker for predicting esophageal cancer immunotherapy effect and prognosis and treatment target Download PDFInfo
- Publication number
- CN116676385A CN116676385A CN202310162695.2A CN202310162695A CN116676385A CN 116676385 A CN116676385 A CN 116676385A CN 202310162695 A CN202310162695 A CN 202310162695A CN 116676385 A CN116676385 A CN 116676385A
- Authority
- CN
- China
- Prior art keywords
- linc02096
- prognosis
- effect
- cells
- esophageal cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 title claims abstract description 58
- 238000011282 treatment Methods 0.000 title claims abstract description 50
- 206010030155 Oesophageal carcinoma Diseases 0.000 title claims abstract description 48
- 208000000461 Esophageal Neoplasms Diseases 0.000 title claims abstract description 43
- 201000004101 esophageal cancer Diseases 0.000 title claims abstract description 43
- 238000004393 prognosis Methods 0.000 title claims abstract description 39
- 239000003550 marker Substances 0.000 title claims abstract description 10
- 238000002619 cancer immunotherapy Methods 0.000 title claims description 6
- 238000009169 immunotherapy Methods 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 29
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 42
- 239000003112 inhibitor Substances 0.000 claims description 28
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 238000011275 oncology therapy Methods 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 abstract description 70
- 206010028980 Neoplasm Diseases 0.000 abstract description 61
- 108091046869 Telomeric non-coding RNA Proteins 0.000 abstract description 30
- 210000001808 exosome Anatomy 0.000 abstract description 28
- 108020004707 nucleic acids Proteins 0.000 abstract description 14
- 102000039446 nucleic acids Human genes 0.000 abstract description 14
- 150000007523 nucleic acids Chemical class 0.000 abstract description 14
- 230000001093 anti-cancer Effects 0.000 abstract description 12
- 230000008685 targeting Effects 0.000 abstract description 10
- 238000001727 in vivo Methods 0.000 abstract description 9
- 238000011160 research Methods 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 208000017897 Carcinoma of esophagus Diseases 0.000 abstract description 5
- 201000005619 esophageal carcinoma Diseases 0.000 abstract description 5
- 230000012010 growth Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 89
- 230000014509 gene expression Effects 0.000 description 54
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 40
- 210000001744 T-lymphocyte Anatomy 0.000 description 39
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 36
- 238000002474 experimental method Methods 0.000 description 33
- 210000002381 plasma Anatomy 0.000 description 30
- 238000001514 detection method Methods 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 18
- 108010074708 B7-H1 Antigen Proteins 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 16
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 15
- 238000000684 flow cytometry Methods 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 108010074328 Interferon-gamma Proteins 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 13
- 238000011529 RT qPCR Methods 0.000 description 13
- 239000000074 antisense oligonucleotide Substances 0.000 description 13
- 238000012230 antisense oligonucleotides Methods 0.000 description 13
- 230000002018 overexpression Effects 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 102000008096 B7-H1 Antigen Human genes 0.000 description 12
- 241000713666 Lentivirus Species 0.000 description 12
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 11
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 11
- 238000010276 construction Methods 0.000 description 11
- 230000004614 tumor growth Effects 0.000 description 11
- 102100037850 Interferon gamma Human genes 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 230000002147 killing effect Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 9
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 229940126546 immune checkpoint molecule Drugs 0.000 description 8
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 description 7
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 108010051779 histone H3 trimethyl Lys4 Proteins 0.000 description 7
- 230000001506 immunosuppresive effect Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000002601 intratumoral effect Effects 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 101710159080 Aconitate hydratase A Proteins 0.000 description 5
- 101710159078 Aconitate hydratase B Proteins 0.000 description 5
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 description 5
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 5
- 101710105008 RNA-binding protein Proteins 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 238000000730 protein immunoprecipitation Methods 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 238000009096 combination chemotherapy Methods 0.000 description 3
- 238000003235 crystal violet staining Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091006010 FLAG-tagged proteins Proteins 0.000 description 1
- 102100030386 Granzyme A Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 description 1
- 101000987581 Homo sapiens Perforin-1 Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108020005198 Long Noncoding RNA Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100028467 Perforin-1 Human genes 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides application of LINC02096 in serving as a marker for predicting the immunotherapy effect and prognosis of esophageal cancer and a therapeutic target. The invention discovers that LINC02096 is exosome LncRNA closely related to the immune treatment effect and prognosis of esophageal squamous carcinoma, can be used as a marker for predicting the immune treatment effect and prognosis of esophageal carcinoma, and can realize the prediction of the immune treatment effect and prognosis of esophageal carcinoma. Further research shows that the LINC02096 knocked out can obviously inhibit the growth of esophageal cancer tumors in vivo; the specific nucleic acid drug targeting LINC02096 has obvious anticancer effect, and can obviously improve the anticancer effect of PD-1 monoclonal antibody when being combined with PD-1 monoclonal antibody.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to application of LINC02096 in serving as a marker for predicting the immunotherapy effect and prognosis of esophageal cancer and a therapeutic target.
Background
Esophageal cancer is the sixth leading cause of global tumor death, and the incidence and death rate of Chinese esophageal cancer are the first in the world. The pathological types of esophageal cancer are mainly squamous carcinoma and adenocarcinoma, of which 90% of cases are esophageal squamous cell carcinoma (esophageal squamous cell carcinoma, ESCC).
In recent years, the development of immunotherapy breaks the bottleneck of treatment of esophageal cancer and rewrites the treatment pattern of esophageal cancer. Immunotherapy represented by the immune checkpoint inhibitor PD-1 monoclonal antibody is continuously advanced from the posterior line to the two lines and the first line in advanced esophageal cancer, and research such as KEYNOTE-590, ESCORT-1 and the like is performed on exploration of different combination modes in advanced esophageal cancer first-line treatment, including immune combination chemotherapy, double-immune combination chemotherapy, targeted combination chemotherapy and the like. Among them, xu Ruihua teaches that the lead ESCORT-1st study was reported in the American Society of Clinical Oncology (ASCO) annual meeting and published results on the international top journal JAMA, showing that the use of carlizumab in combination with paclitaxel and cisplatin for advanced esophageal cancer first-line treatment significantly improved the progression free survival (6.9 vs 5.6 months) and overall survival (15.3 vs 12.0 months) of the patient. The data of the research is encouraging to promote the application of domestic PD-1 monoclonal antibodies in advanced esophageal cancer, however, only partial patients can benefit from the durable curative effect and long-term survival in immunotherapy despite the results of the existing research, so that the biomarker is explored to realize the accurate screening of the immunotherapy, the crowd which can truly benefit from the immunotherapy is positioned, and the unnecessary cost and the drug toxicity of patients with unresponsiveness are avoided.
The exosomes are vesicles which are secreted by cells and have a size of 30-100 nm, and which contain bioactive substances such as lipids, proteins, mRNA, miRNA, lncRNA, etc., and which can exert biological functions by binding to target cell receptors or transmitting bioactive substances at a level. It has been found that they are capable of modulating host-pathogen interactions, involved in the pathological processes of a wide variety of diseases, such as infectious and inflammatory diseases, neurological diseases and cancers. Exosomes contain abundant biomarkers that can be used to monitor clinical status, therapeutic response, disease progression, etc. Long non-coding RNA (lncRNA) is a class of transcription products of RNA polymerase II that are greater than 200 nucleotide sequences in length, located in the nucleus or cytoplasm. Since lncRNA lack a distinct open reading frame, they do not have the function of encoding proteins, and they were initially considered to be "noise" in the transcription process. However, recent studies have shown that lncRNAs are abnormally expressed in a variety of tumors and play an important regulatory role in the proliferation, migration, apoptosis and metastasis processes of cells. In the tumor growth process, lncRNA can directly participate in the expression regulation of protein coding genes in RNA form through various layers, such as chromatin modification, epigenetic marking, gene transcription control, mRNA combined with the regulation after transcription, and the like.
In the prior art, the plasma exosome lncRNA is used as a biomarker for diagnosing esophageal squamous cell carcinoma, but no report that the plasma exosome lncRNA is used as a biomarker for predicting the immunotherapy effect and prognosis of esophageal squamous cell carcinoma is found.
Disclosure of Invention
The invention aims to solve the technical problem of exploring a technology capable of predicting esophageal cancer patients with good immunotherapy effect, and can be used for clinically guiding esophageal cancer treatment schemes and medication schemes.
It is a primary object of the present invention to provide the use of LINC02096 for predicting the effect and/or prognosis of immunotherapy of esophageal cancer.
It is a further object of the invention to provide the use of LINC02096 as a marker for predicting the effect and/or prognosis of immunotherapy of esophageal cancer.
It is a further object of the invention to provide the use of a reagent for detecting LINC02096 for the preparation of a kit for predicting the immunotherapeutic effect and/or prognosis of esophageal cancer.
It is a further object of the invention to provide the use of LINC02096 as a target for the treatment of esophageal cancer.
It is a further object of the invention to provide the use of LINC02096 as a drug target for the treatment of esophageal cancer.
It is a further object of the invention to provide the use of LINC02096 inhibitors for the manufacture of a medicament for the treatment of esophageal cancer.
It is a further object of the invention to provide the use of LINC02096 inhibitors in combination with PD-1 antibodies for the manufacture of a medicament for the treatment of esophageal cancer.
It is still another object of the present invention to provide a medicament for treating esophageal cancer.
It is a further object of the invention to provide a kit for predicting the effect and/or prognosis of immunotherapy of esophageal cancer.
The invention achieves the aim by the following technical means:
the invention extracts plasma exosome lncRNA of esophageal squamous carcinoma patients with effective and ineffective immunotherapy, analyzes LINC02096 to be exosome LncRNA closely related to the immunotherapy effect and prognosis of esophageal squamous carcinoma, and clarifies the related action mechanism of LINC02096 on the immunotherapy effect and prognosis of esophageal squamous carcinoma, wherein the high expression of LINC02096 reduces infiltration of tumor immune cells and immune killing activity, and LINC02096 promotes expression of immunosuppressive molecules through KMT2A-H3K4me 3.
In addition, the invention also discovers that LINC02096 knockout can obviously inhibit the growth of esophageal squamous carcinoma tumor in vivo, and PD-1 antibody combined can further inhibit the growth of esophageal squamous carcinoma tumor in vivo; the specific nucleic acid drug (LINC 02096 inhibitor) targeting LINC02096 has remarkable anticancer effect and can improve the anticancer effect of PD-1 monoclonal antibody.
Based on the experimental results, the following technical schemes are also within the protection scope of the invention.
The invention provides an application of LINC02096 in predicting the immune therapeutic effect and/or prognosis of esophageal cancer, wherein the Gene ID of LINC02096 in NCBI is 107984977.
The invention also provides application of LINC02096 in serving as a marker for predicting the immune treatment effect and/or prognosis of esophageal squamous carcinoma.
The invention also provides application of the LINC02096 detection reagent in preparation of a kit for predicting the immunotherapy effect and/or prognosis of esophageal cancer.
Preferably, the reagent for detecting LINC02096 is a reagent used for qPCR.
The invention also provides application of LINC02096 in serving as an esophageal cancer treatment target.
The invention also provides application of the LINC02096 inhibitor in preparing medicines for treating esophageal cancer.
The invention also provides application of the LINC02096 inhibitor in preparing a synergist of an esophageal cancer immunotherapy drug.
The invention also provides application of the LINC02096 inhibitor combined with the PD-1 antibody in preparing medicines for treating esophageal cancer.
The invention also provides a medicament for treating esophageal cancer, which is characterized by containing an inhibitor of LINC02096.
Preferably, the medicament further comprises a PD-1 antibody.
Preferably, the medicament further comprises pharmaceutically acceptable excipients.
Preferably, the inhibitor of LINC02096 is a specific nucleic acid agent targeting LINC02096.
More preferably, the nucleotide sequence of the LINC 02096-targeting specific nucleic acid agent is 5'-AGCGCACCGAAAGGAAC CAA-3'.
The invention also provides a kit for predicting the immunotherapy effect and/or prognosis of esophageal cancer, which is characterized by containing a reagent for detecting LINC02096.
Preferably, the esophageal cancer is esophageal squamous carcinoma.
The invention has the following beneficial effects:
according to the analysis of the invention, LINC02096 is exosome LncRNA closely related to the immune treatment effect and prognosis of esophageal squamous carcinoma, can be used as a biomarker for predicting the immune treatment effect and prognosis of esophageal carcinoma, realizes the prediction of the immune treatment effect and prognosis of esophageal carcinoma, and has important significance for guiding the treatment and drug regimen selection of clinical esophageal carcinoma patients.
Further research shows that the LINC02096 knocked out can obviously inhibit the growth of esophageal squamous carcinoma tumor in vivo; the specific nucleic acid drug targeting LINC02096 has obvious anticancer effect and can improve the anticancer effect of PD-1 monoclonal antibody.
Drawings
FIG. 1 is a graph showing the results of analysis of the effects of LINC02096 on esophageal squamous carcinoma immunotherapy and prognostic relevance, wherein; FIG. 1A shows the Disease Control Rate (DCR) and Objective Remission Rate (ORR) after treatment with PD-1 mab corresponding to the plasma exosome LINC02096 high and low expression group; FIG. 1B shows the DCR and ORR of LINC02096 high and low expression sets in tumor tissues after treatment with PD-1 mab; FIG. 1C shows total survival (OS) following treatment with PD-1 mab corresponding to the plasma exosome LINC02096 high and low expression group; FIG. 1D shows Progression Free Survival (PFS) following treatment with PD-1 mab corresponding to the plasma exosome LINC02096 high and low expression group.
FIG. 2A is a graph showing the results of analysis of the correlation between LINC02096 expression level and tumor immune cell infiltration and immune killing activity; FIG. 2B shows the expression of LINC02096 knockout cell line immune checkpoint molecules detected by an immune checkpoint chip; FIG. 2C shows the detection of LINC02096 knockout cell line and the expression of immune checkpoint molecule of over-expression cell line by flow cytometry.
FIG. 3A shows the results of an experiment to identify a target protein of LINC02096 that performs a biological function by RNA Pulldown experiment and WB; FIG. 3B is an experimental result of a RIP experiment verifying that LINC02096 specifically binds to KMT 2A; FIG. 3C is an experimental result of MS2-TRAP experiment to verify that LINC02096 specifically binds to KMT 2A; FIG. 3D shows H3K4me3 levels of PD-L1 promoter after ChIP-qPCR detection of LINC02096 knockout; FIG. 3E shows H3K4me3 levels of the IDO-1 promoter after the LINC02096 knockout by ChIP-qPCR.
FIG. 4 is a knockout LINC02096 in vitro CD8 + Effect of T cells on killing activity of esophageal squamous carcinoma cells; wherein, fig. 4A and fig. 4B are graphs of results and statistical graphs of experiments of killing esophageal squamous carcinoma cells by T cells in vitro after crystal violet staining and statistics of LINC02096 knockout; FIG. 4C shows the detection of CD8 + Experimental results of lactate dehydrogenase levels released by tumor cell lysis death in culture medium supernatants of T cells co-cultured with esophageal squamous carcinoma cells; FIG. 4D shows the detection of CD8 + CD8 in culture medium supernatant of co-culture of T cells and esophageal squamous carcinoma cells + Experimental results of interferon IFN-gamma levels secreted by T cells.
FIG. 5A is the effect of knockdown LINC02096 and PD-1 antibodies in combination on tumor growth in esophageal squamous carcinoma; FIG. 5B shows the tumor growth curve, tumor weight, and flow cytometry detection of intratumoral CD8 for huPBMC-NOG-CDX model + T cells and IFN-gamma + CD8 + T cell ratio; FIG. 5C is a flow cytometry detection of intratumoral IFN-gamma + CD8 + Representative plot of T cell ratio; FIG. 5D shows the multiplex immunohistochemical detection of intratumoral CD8 + T cells and GranB + CD8 + T cell ratio.
FIG. 6 shows the effect of tail intravenous LINC02096-inhibitor and PD-1 monoclonal antibody on esophageal squamous carcinoma tumor volume, tumor weight and flow cytometry detection of intratumoral CD8 in huPBMC-NOG-PDX model + T cells and IFN-gamma + CD8 + T cell ratio; RIME inhibitor in the figure represents LINC02096-inhibitor.
Detailed Description
The invention is further illustrated in the following drawings and specific examples, which are not intended to limit the invention in any way. Unless specifically stated otherwise, the reagents, methods and apparatus employed in the present invention are those conventional in the art.
Reagents and materials used in the following examples are commercially available unless otherwise specified.
EXAMPLE 1 identification of plasma exosomes LncRNA associated with the Effect and prognosis of esophageal squamous carcinoma immunotherapy
1. Screening candidate plasma exosome LncRNA related to esophageal squamous carcinoma immunotherapy effect and prognosis
1. Collecting a plasma sample:
10 patients with effective and ineffective treatment in esophageal squamous carcinoma PD-1 monoclonal antibody (terep Li Shan antibody) single drug treatment queues (from university of Zhongshan tumor prevention center) were collected, and 20 patients were treated.
Judgment principle of selecting specimens (treatment effective and ineffective): post-treatment imaging of PD-1 mab assessed as either Partial Remission (PR) or Complete Remission (CR) as "effective", and post-treatment imaging of PD-1 mab assessed as "ineffective" for disease Progression (PD).
2. Plasma exosomes LncRNA pooling:
extracting plasma exosomes by using an ultracentrifugation method, carrying out LncRNA library establishment and belief analysis, determining 10 plasma exosomes LncRNA before the patient with ineffective PD-1 monoclonal antibody treatment expression level, taking the 10 plasma exosomes LncRNA as candidate plasma exosomes LncRNA, and further screening and identifying the plasma exosomes LncRNA related to the immune treatment effect and prognosis of esophageal squamous carcinoma.
2. Screening and identifying plasma exosome LncRNA associated with esophageal squamous carcinoma immunotherapy effect and prognosis
1. Analysis of expression level of candidate plasma exosomes LncRNA and treatment effect and prognosis correlation of PD-1 monoclonal antibody
(1) Experimental method
Respectively detecting the expression levels of the 10 candidate plasma exosomes LncRNA in the plasma of 58 esophageal squamous carcinoma patients by using a qPCR method, and calculating the average expression quantity of each candidate plasma exosomes LncRNA; and (3) the patients with the plasma exosome LncRNA expression level higher than the average expression level are classified as a high expression group, the patients with the plasma exosome LncRNA expression level lower than the average expression level are classified as a low expression group, and the treatment effect and the prognosis index of the patients with the LncRNA high-low expression group treated by the PD-1 monoclonal antibody are compared.
The primer sequences of LINC02096 used for qPCR described above are as follows:
LINC02096 forward primer sequence is shown as SEQ ID NO.1, specifically: 5'-TTCTGAGGCCCACGATAAGC-3';
LINC02096 reverse primer sequence is shown as SEQ ID NO.2, specifically: 5'-TGGAGATGTGAGTTGCTGCC-3';
the treatment effect and prognosis index comprise: disease control rate DCR, objective remission rate ORR, total survival OS, progression Free Survival (PFS).
(2) Experimental results
The results show that the expression level of plasma LINC02096 is obviously and negatively related to the curative effect and prognosis of PD-1 monoclonal antibody through verification, as shown in figure 1A. The disease control rate DCR and objective remission rate ORR of the plasma LINC02096 high-expression group are lower than those of the LINC02096 low-expression group (figure 1A), which shows that the effect of the plasma LINC02096 high-expression immunotherapy is poor.
The results primarily suggest that LINC02096 is a key exosome LncRNA with negative correlation to esophageal squamous carcinoma immunotherapy effect and prognosis.
2. Transcriptome sequencing of tumor tissue
And collecting tumor tissues of 29 esophageal squamous carcinoma patients before treatment, extracting RNA, performing a conventional flow of transcriptome sequencing, and analyzing the correlation between the expression level of LINC02096 in the tumor tissues and the treatment effect and prognosis of PD-1 monoclonal antibody.
In this experiment, the sample column in which LINC02096 expression can be detected by transcriptome analysis is a LINC02096 high expression group (5 cases), the sample column in which LINC02096 cannot be detected is a LINC02096 low expression group (24 cases), and the therapeutic effect and prognostic index of the LncRNA high-low expression group are compared: disease control rate DCR, objective remission rate ORR, total survival OS, progression Free Survival (PFS).
(2) Experimental results
The analysis results of the correlation of LINC02096 expression level in tumor tissue and esophageal squamous carcinoma immunotherapy effect and prognosis are shown in FIG. 1B. The results show that the LINC02096 high expression group PD-1 monoclonal antibody in tumor tissues has lower Disease Control Rate (DCR) and Objective Remission Rate (ORR).
In addition, the total survival time OS and the progression-free survival time PFS of the plasma LINC02096 high expression group are both shortened compared with those of the LINC02096 low expression group (fig. 1C and 1D), which proves that the survival prognosis of patients with esophageal squamous cell carcinoma with high expression of plasma LINC02096 is poorer.
In combination with the results, LINC02096 in blood plasma and tumor tissues is highly expressed, PD-1 monoclonal antibody is used for treatment, and the Disease Control Rate (DCR) and Objective Remission Rate (ORR) of the treatment effect are low; and plasma LINC02096 is highly expressed, and the total survival time (OS) and the progression-free survival time (PFS) are obviously shortened when the PD-1 monoclonal antibody is used for treatment.
The results show that LINC02096 is exosome LncRNA closely related to the immune treatment effect and prognosis of the esophageal squamous cell carcinoma, and the expression quantity of LINC02096 is inversely related to the immune treatment effect and prognosis of the esophageal squamous cell carcinoma.
Example 2 Regulation and molecular mechanisms of LINC02096 on tumor immune microenvironment and immune-related factors
To further explore the mechanism by which LINC02096 is responsible for immune therapy non-response and poor prognosis, this example uses bioinformatics to analyze the relevance of LINC02096 to tumor microenvironment.
1. Exploration of the relevance of LINC02096 to the tumor microenvironment
The relevance of LINC02096 and the tumor microenvironment of the esophageal squamous carcinoma patient is analyzed through a biological information technology, and the relevance of LINC02096 and the tumor microenvironment of the esophageal squamous carcinoma patient is analyzed based on TCGA transcriptome data and CIBERSORT algorithm.
As shown in FIG. 2A, it can be seen that LINC02096 expression level and PRF1, GZMA and other tumor immune killing activity indexes have negative correlation trend, and CD8 + Tumor infiltration of cells such as T cells, NK cells, and M1 type macrophages is also inversely related. The results show that the expression level of LINC02096 has a negative correlation trend with tumor immune cell infiltration and immune killing activity.
2. Effect of LINC02096 on immune-related factor expression
The effect of LINC02096 on the expression level of tumor cell immune related molecules is analyzed by an immune check point chip and a flow cytometry technology.
1. Experimental method
(1) Construction of LINC02096 knockout cell line (KO)
LINC02096 knockdown esophageal squamous carcinoma cell lines were constructed using CRISPR technology using two esophageal squamous carcinoma cell lines, KYSE520 and KYSE-70, respectively. The specific process is as follows:
s1, construction of lentiviruses
Constructing a knockdown lentivirus for transfection of an esophageal squamous carcinoma cell line knocked down by LINC02096, wherein the knockdown lentivirus is constructed as follows: pLV_U6-LINC02096 sgRNA01-gRNA Backbone-7SK master-LINC 02096 sgRNA02-gRNA Backbone-EFS-hCAs9-2A-Puro,
the sequence of LINC02096 sgRNA01 (human) is shown as SEQ ID NO.3, and specifically comprises the following steps: 5'-CCCCCACCCGTCACCACCTT-3';
the sequence of LINC02096 sgRNA02 (human) is shown in SEQ ID NO.4, and specifically comprises: 5'-AACAAAATGACTAAGCACCG-3';
meanwhile, the knockdown control lentivirus is constructed for constructing a knockdown control cell line, and the knockdown control lentivirus is constructed as follows: pLV_U6-NC sgRNA01-gRNA backbond-7 SK pro-NC sgRNA02-gRNA backbond-EFS-hCAs 9-2A-Puro,
the NC sgRNA01 (human) has a sequence shown in SEQ ID NO.5, and specifically comprises the following components: 5'-GGAATCCGGAGCTCATGAGG-3';
the sequence of NC sgRNA02 (human) is shown as SEQ ID NO.6, specifically: 5'-TAACCCAGAAGCCCATTCAG-3';
s2, constructing LINC02096 knocked-out esophageal squamous carcinoma cell line by transfection knocked-out lentivirus
At 37℃with 5% CO 2 In the cell culture box of (2), human esophageal squamous carcinoma cell lines KYSE-70 and KYSE520 are cultured, liquid is changed for 1 time every 48 hours, and when the cell density reaches 80 percent, the passages are carried out. Cells grown in log phase were taken at 1X 10 5 Inoculating the individual cells/holes into a 6-hole plate until the cell confluency reaches 30% -40%, constructing a LINC02096 knockdown esophageal squamous carcinoma cell line by using the knockdown lentivirus transfected esophageal squamous carcinoma cell line (KYSE-70, KYSE 520), and simultaneously constructing a knockdown control cell line by using the knockdown control lentivirus transfected esophageal squamous carcinoma cell line (KYSE-70, KYSE 520); and (3) screening puromycin for 1 week, then digesting and plating cells to a 96-well plate, after a plurality of weeks, selecting monoclonal holes, extracting cellular RNA, carrying out qPCR experiments, detecting the expression level of LINC02096, and amplifying the cell strain which is stably knocked out by LINC02096 compared with a knocked-out control cell line, namely a monoclonal cell strain which is not expressed by LINC02096, so as to obtain the esophageal squamous cell line knocked out by LINC02096.
(2) Construction of LINC02096 overexpressing cell line (OE)
Two esophageal squamous carcinoma cell lines, KYSE520 and KYSE-70, were used respectively, and a LINC02096 over-expression esophageal squamous carcinoma cell line was constructed by using a lentiviral transfection technique. The specific process is as follows:
s1, construction of lentiviruses
And constructing an over-expression lentivirus, and constructing a LINC02096 over-expression esophageal squamous carcinoma cell line by transfection, wherein the element of the over-expression lentivirus after construction is pLenti-EF1a-F2A-Puro-CMV-LINC02096. Meanwhile, the over-expression control slow virus is constructed and used for constructing an over-expression control cell line, and the element after construction of the over-expression control slow virus is pLenti-EF1a-F2A-Puro-CMV-MCS.
S2, constructing LINC02096 over-expressed esophageal squamous carcinoma cell line by transfection over-expressed lentivirus
At 37℃,5％CO 2 In the cell culture box of (2), human esophageal squamous carcinoma cell lines KYSE-70 and KYSE520 are cultured, liquid is changed for 1 time every 48 hours, and when the cell density reaches 80 percent, the passages are carried out. Cells grown in log phase were taken at 1X 10 5 Inoculating the cells/holes into a 6-hole plate until the cell confluency reaches 30% -40%, using LINC02096 over-expression slow virus to transfect esophageal squamous carcinoma cell lines (KYSE-70, KYSE 520) to construct LINC02096 over-expression esophageal squamous carcinoma cell lines, and simultaneously using the over-expression control slow virus to transfect esophageal squamous carcinoma cell lines (KYSE-70, KYSE 520) to construct an over-expression control cell line; and (3) screening puromycin for 1 week, then digesting and plating cells to a 96-well plate, after a plurality of weeks, selecting monoclonal holes, extracting cellular RNA, carrying out qPCR experiments, detecting the expression level of LINC02096, and amplifying the LINC02096 over-expressed cell strain to obtain the LINC02096 over-expressed esophageal squamous cell line, wherein the monoclonal cell strain with the expression obviously increased compared with the LINC02096 of the over-expressed control cell line is successful.
(3) Effect of LINC02096 on immune-related factor expression
The experiment detects the influence of LINC02096 on a series of immune check point molecules by constructing a chip of immune related molecules (immune check point chip), and further verifies the expression level of the related immune check point molecules by a flow cytometry technology.
The experimental procedure for detecting the effect of LINC02096 on a series of immune checkpoint molecules by means of an immune checkpoint chip is as follows: primers of a plurality of (see specifically fig. 2B) immune check point molecular genes such as PD-L1, HLA-B, HLA-C and the like, PCRmix and enzyme-free water are respectively added into a Roche 384-well plate to prepare an immune check point PCR chip, and finally cDNA of a LINC02096 knocked-out esophageal squamous carcinoma cell line (KYSE 520) is added to carry out a qPCR experiment. The expression level of the relevant immune checkpoint molecule was verified by conventional immunoblotting.
Expression levels of PDL1, IDO1 were then verified by conventional flow cytometry techniques:
cells of LINC02096 knockout esophageal squamous carcinoma cell line (KYSE 520) and LINC02096 overexpressing esophageal squamous carcinoma cell line (KYSE 520) were collected, resuspended in appropriate amount of cell staining buffer (1% BSA in PBS), stained with PDL1, IDO1 antibody for 30min at 4deg.C in the absence of light, washed twice, the supernatant was discarded, 200uL of PBS was added to resuspend cells, and detection and analysis were performed with flow cytometry.
2. Experimental results
The expression condition of the immune checkpoint chip for detecting the LINC02096 knockout cell line immune checkpoint molecules is shown as a figure 2B, and the obvious down regulation of the expression level of the immune inhibitory molecules such as PD-L1, IDO1 and the like of tumor cells after LINC02096 knockout is found.
The effect of flow cytometry detection LINC02096 knockout or overexpression on tumor cell PD-L1 and IDO1 expression results are shown in FIG. 2C, and it can be seen that the expression levels of the PD-L1 and IDO1 of the tumor cells after LINC02096 knockout are obviously reduced; the opposite effect was shown in LINC02096 over-expressed cell lines, and the expression levels of PD-L1 and IDO1 were significantly increased, indicating that LINC02096 is a key factor in promoting the expression of tumor cell immunosuppressive molecules such as PD-L1 and IDO1 (FIG. 2C).
The results of FIGS. 2B and 2C demonstrate that expression of LINC02096 can promote expression of tumor cell immune checkpoint molecules such as PD-L1 and IDO-1, and participate in immune escape of tumor cells.
3. Identification of key target proteins of LINC02096 for biological function
1. Screening LINC 02096-bound target proteins
Protein mass spectrometry was combined using the RNA Pulldown method, excluding non-specifically bound proteins from the antisense strand control group, and a key target molecule for LINC02096 function was explored. The specific method comprises the following steps:
(1) RNA Pulldown method
To explore the molecular mechanisms by which LINC02096 inhibits immune cell infiltration and promotes expression of immunosuppressive molecules, we identified proteins that specifically bind to LINC02096.
The operation procedure of the RNA Pulldown kit (Sieimer's fly) was followed: by MEGAscript TM T7Transcription Kit in vitro transcribed LINC02096 sense and antisense strands, biotin-labeled with Pierce RNA 3'End Desthiobiotinylation Kit, and RNA pull described below was performed using the biotin-labeled LINC02096 sense and antisense strands, respectivelyAnd (5) down experiment. Culturing human esophageal squamous carcinoma cell lines KYSE-70 and KYSE520, extracting cell Protein lysate, performing RNA pulldown experiment according to a Sieimer flight Kit Pierce Magnetic RNA-Protein Pull-Down Kit, collecting eluted Protein, performing LC-MS/MS detection, screening Protein interacted with LINC02096, and verifying through western blot.
(2) Experimental results
The results of the RNA Pulldown experiment and WB validation are shown in FIG. 3A. It can be seen that LINC02096 sense strand (AS) was able to bind to histone methyltransferase KMT2A, whereas antisense strand (S) control was unable to bind to KMT2A, indicating that LINC02096 binding to histone methyltransferase KMT2A is specific. The results indicate that LINC02096 binds to histone methyltransferase KMT 2A.
2.LINC 02096-KMT2A binding specificity verification
The specificity of LINC02096-KMT2A binding was further verified by in vitro and in vivo RNA-protein interaction experiments. In vitro and in vivo RNA-protein interaction assays include RNA binding protein immunoprecipitation (RIP assay), MS 2-labeled RNA affinity purification (MS 2-TRAP assay), and the following methods are specific:
(1) Experimental method
A. RNA binding protein immunoprecipitation
RNA binding protein immunoprecipitation experiments on esophageal squamous carcinoma cell lines KYSE520 and KYSE70 were carried out by using a Magna RNA-binding protein immunoprecipitation kit kit to verify the binding specificity of LINC02096-KMT2A, and the specific steps are as follows:
s1, preparing cell lysate: and (3) using RIP lysate to lyse cells on ice, and sub-packaging the lysate for later use.
S2, preparing magnetic beads: after the magnetic beads were resuspended, 50. Mu.L of each sample was washed twice with 500. Mu.L of RIP wash buffer.
S3, magnetic bead-antibody binding: the beads were resuspended in 100. Mu.L of RIP wash buffer, and approximately 5. Mu.L of target or control IgG antibody was added and incubated for 30min at room temperature.
S4, immunoprecipitation of RNA binding protein: RIP immunoprecipitation Buffer was prepared, 900. Mu.L of RIP immunoprecipitation Buffer and 100. Mu.L of cell lysis supernatant were added to each tube, and incubated overnight at 4 ℃.
S5, washing: the beads were recovered, the supernatant discarded, 500. Mu.L of RIP wash buffer was added and the wash repeated 6 times.
S6, preparing proteinase K Buffer (117 mu L of RIP washing Buffer, 15 mu L of 10% SDS and 18 mu L of RNase proteinase K), wherein 150 mu L of each sample is needed; mixing, and incubating at 55deg.C for 30min.
S7, RNA purification: the supernatant was collected and 400. Mu.L of phenol was added to each tube: chloroform: isoamyl alcohol extraction, adding 5 μl of salt solution I, 15 μl of salt solution II, 5 μl of precipitation enhancer, 850 μl of absolute ethanol, and standing overnight;
s8, cleaning the sample with 80% ethanol, airing at room temperature, dissolving 20 mu L of enzyme-free water, and carrying out PCR or sequencing.
B. MS 2-labeled RNA affinity purification
S1 ESCC cells (KYSE 70 cell line) were co-transfected with pcDNA3.1-MS2 or pcDNA3.1-MS2-LINC02096 and MCP-3xFLAG plasmid.
After S2.48 hours, the cells were washed with PBS and the liquid was blotted off, the plates were placed on ice and irradiated with 254nm UV light at 400mJ/cm 2 Living cells are irradiated.
S3, using WB and IP lysate (containing protease phosphatase inhibitor) to lyse cells on ice for 15 min, centrifuging at 13,000Xg and 4 ℃ for 10min.
S4 immunoprecipitation was performed with anti-FLAG M2 affinity gel (Sigma-Aldrich, USA) to bind FLAG-tagged proteins.
S5, washing the anti-FLAG M2 affinity gel 3 times by using PBS buffer, adding 40 microliters of 1 XSDS-PAGE loading buffer, and heating at 95 ℃ for 10min to denature proteins.
S6, analyzing the FLAG-MCP-MS2-RNA protein complex by western blotting.
(2) Experimental results
FIG. 3B is an experimental result of a RIP experiment verifying that LINC02096 specifically binds to KMT 2A; it can be seen that KMT2A can be combined with LINC02096 endogenous in the cell, corresponding nucleic acid bands can be identified through RT-PCR and agarose gel electrophoresis, and IgG control group can not be combined with LINC02096, and the reverse verification that LINC02096 can be combined with KMT 2A;
FIG. 3C is an experimental result of MS2-TRAP experiment to verify that LINC02096 specifically binds to KMT 2A. It can be seen that MS 2-labeled LINC02096 was able to bind to KMT2A in cells, whereas MS 2-labeled control RNA was unable to bind to KMT2A in cells. MS2-TRAP experiments demonstrated that LINC02096 can bind to KMT2A in vivo.
3. LINC02096-KMT2A interaction regulates transcription of tumor cell immunosuppressive molecules through H3K4me3
The experiment researches the LINC02096-KMT2A interaction to regulate the transcription of tumor cell immunosuppressive molecules through H3K4me3 by combining with ChIP through a messenger assay.
(1) ChIP-qPCR experiment
Detection was performed using the ChIP kit. KYSE-70, KYSE520, LINC02096 knockout cell line KYSE-70, LINC02096 knockout cell line KYSE520 genome DNA are fixed, lysed and sheared by ultrasound. After detecting the shearing effect by agarose gel electrophoresis, respectively adding an anti-H3K 4me3 antibody, a control IgG antibody and magnetic beads into the supernatant, incubating and washing, performing DNA purification to obtain a purified product, designing primers according to a section with biological prediction binding, performing qRT-PCR quantification, and verifying whether the trimethylated histone (H3K 4me 3) of the third subunit IV is enriched in PD-L1 and IDO-1 gene promoters;
the primer sequences of the PD-L1 gene and IDO-1 gene promoters used in qRT-PCR quantitative analysis are as follows:
the forward primer sequence of the PD-L1 gene promoter is shown as SEQ ID NO.7, and specifically comprises the following components: PD-L1 Gene promoter Forward primer: 5'-GCCCATTCACTAACCCAAAGC-3';
the reverse primer sequence of the PD-L1 gene promoter is shown as SEQ ID NO.8, and specifically comprises the following components: PD-L1 Gene promoter reverse primer: 5'-AAAGAACTTCCCATCCCGAGC-3'.
The IDO-1 gene promoter primer sequence is as follows:
the sequence of the forward primer of the IDO-1 gene promoter is shown as SEQ ID NO.9, and specifically comprises the following steps: IDO-1 gene promoter forward primer: 5'-CGTTGTTCCATGTCTTCACT-3';
the reverse primer sequence of the IDO-1 gene promoter is shown as SEQ ID NO.10, and specifically comprises the following components: IDO-1 gene promoter reverse primer: 5'-CTTTGGGAATCAGTTCAAGG-3'.
(2) Experimental results
The experimental results are shown in FIG. 3D and FIG. 3E, wherein FIG. 3D is the H3K4me3 level of the PD-L1 promoter after LINC02096 knockout by ChIP-qPCR detection; FIG. 3E shows H3K4me3 levels of the IDO-1 promoter after the ChIP-qPCR assay knockdown of LINC02096. It can be seen that after LINC02096 is knocked out, the level of H3K4me3 of the immunosuppressive molecules PD-L1 and IDO-1 promoters is obviously reduced, and the transcription level is inhibited. The results indicate that LINC02096-KMT2A interactions promote immunosuppressive molecule expression through H3K4me 3.
In view of the experimental results, LINC02096 regulates and controls the transcription level of the target gene immune checkpoint molecule through KMT2A-H3K4me 3.
Example 3 knockout of LINC02096 in vitro CD8 + Effect of T cells on killing Activity of esophageal squamous carcinoma cells
1. Experimental method
Isolation of human peripheral blood CD8 + T cells were co-cultured with LINC02096 knocked out esophageal squamous carcinoma cells, KYSE70 or KYSE520, at a ratio of 10:1 for 12 hours, medium supernatants were collected against non-LINC 02096 knocked out esophageal squamous carcinoma cells, KYSE70 or KYSE520, interferon IFN- γ levels were detected using ELISA kit (ab 174443, abcam) according to manufacturer's instructions, and Lactate Dehydrogenase (LDH) detection kit (ab 102526, abcam) was used to detect LDH levels. The remaining surviving tumor cells were subjected to crystal violet staining and the cell numbers were counted.
2. Experimental results
The experimental results are shown in FIG. 4. Wherein, fig. 4A and fig. 4B are graphs of results and statistical graphs of experiments of killing esophageal squamous carcinoma cells by T cells in vitro after crystal violet staining and statistics of LINC02096 knockout; FIG. 4C shows the detection of CD8 + Experimental results of lactate dehydrogenase levels released by tumor cell lysis death in culture medium supernatants of T cells co-cultured with esophageal squamous carcinoma cells; FIG. 4D shows the detection of CD8 + CD8 in culture medium supernatant of co-culture of T cells and esophageal squamous carcinoma cells + Experimental results of interferon IFN-gamma levels secreted by T cells.
It can be seen that when LINC02096 is knocked out, CD8 + Tumor cell depletion in survival following co-culture of T cells with esophageal squamous carcinoma cells (FIG. 4A,Panel B) increased lactate dehydrogenase LDH released by lysis of killed tumor cells (FIG. 4C), CD8 + The elevated levels of interferon IFN-gamma secreted by T cells (FIG. 4D) demonstrate that LINC02096 knockdown enhances the killing activity of CD8+ T cells against esophageal squamous carcinoma cells, helping to inhibit survival of esophageal squamous carcinoma cells in the tumor microenvironment.
Examples 4-6 below explore the therapeutic strategy of targeting LINC02096 in humanized immunized mice and anticancer effect of combined immunotherapy.
Example 4 Effect of LINC02096 knockout on tumors in esophageal squamous carcinoma bodies
1. Experimental grouping
A. Control group: KYSE520+IgG;
B. PD-1 mab experimental group: KYSE520+PD-1 monoclonal antibody;
C. knock-out LINC02096 experimental group: LINC02096 knockdown KYSE520+IgG;
D. knockdown LINC02096 in combination with PD-1 mab experimental group: LINC02096 knockdown KYSE520+PD-1 monoclonal antibody.
2. Experimental method
1. Construction of LINC02096 knockout esophageal squamous carcinoma cell line
LINC02096 knockout esophageal squamous carcinoma cell line (KYSE 520) was constructed using CRISPR technology and the procedure was as in example 2.
2. Construction of immune System humanized cell line transplantation tumor model huPBMC-NOG-CDX
Human PBMC (from healthy volunteers) were transplanted by tail vein injection in NOG immunodeficient mice (Beijing Veitzerland) at an injection rate of 1X 10 7 Only, a mouse model of immune system humanization (huPBMC-NOG) was constructed. The line KYSE520 from esophageal squamous carcinoma cells KYSE520 or LINC02096 knockout KYSE520 was inoculated subcutaneously in huPBMC-NOG according to the above experimental group, and the injection amount was 1×10 7 Only, huPBMC-NOG-CDX models were constructed.
3. Animal experiment
After the huPBMC-NOG-CDX model described above was developed, solid tumors formed at the injection site were measured every 3 days using digital calipers and tumor volumes were calculated using the following equation: tumor volume = length xWidth of (L) 2 2; in mm 3 . When the tumor grows to about 100mm 3 At the same time, according to the above group, the corresponding treatments are given respectively: igG and PD-1 antibody were administered 1 time every 3 days at a dose of 200 μg/mouse by intraperitoneal injection for 3 total treatments; tumor volume was measured every 3 days when tumor volume of any one mouse reached 2000mm 3 At the same time, all the test mice are euthanized by cervical dislocation, the tumor volumes are counted, and the treatment effect differences among different treatment groups are compared. The body weight of the mice was examined every 3 days during the course of the experiment, and was not significantly reduced (10% of body weight was not reduced), suggesting no severe immune rejection.
And (II) detecting the proportion of each immunocyte subgroup in the tumor by using flow cytometry and multiple immunohistochemistry.
(1) Flow cytometry
Tumor tissue is taken and placed in RPMI-1640 medium, the tumor tissue is separated and cut into small pieces, and mechanical dissociation is carried out by using a dissociator. Collagenase I, DNA enzyme was added and incubated at 37℃for 30 minutes. The digested tumor tissue was collected, the single cell suspension was filtered through a single cell screen to a centrifuge tube, and erythrocytes were lysed by addition of buffered ammonium chloride. The cell is dyed by using different flow antibodies, and the marker on the surface of the cell membrane is dyed first, and the marker in the cell plasma is dyed after the membrane is broken. Analysis of CD4 in tumors further using flow cytometry + T cells, CD8 + The proportion of cell components such as T cells, macrophages and the like, and simultaneously co-staining a CD8+ T cell activation index (IFN-gamma), and evaluating the activation condition of the CD8+ T cells in tumor tissues.
(2) Multiplex immunohistochemistry
Fixing mouse tumor tissue in paraformaldehyde solution, embedding in paraffin, slicing, co-staining with corresponding antibody (CD 8, PD-L1, granzyme B), photographing with confocal microscope, and evaluating CD8 in tumor tissue + T cells and Granzyme B + Infiltration of killer T cells.
3. Experimental results
The experimental results are shown in FIG. 5, wherein FIG. 5A shows the in vivo tumor growth of LINC02096 knockout and PD-1 antibody combination on esophageal squamous carcinomaIs a function of (1); FIG. 5B shows huPBMC-NOG-CDX model tumor growth curves and flow cytometry for intratumoral IFN-gamma detection + CD8 + T cell ratio; FIG. 5C is a flow cytometry detection of intratumoral IFN-gamma + CD8 + T cell ratio; FIG. 5D shows the detection of GranB in tumor by multiplex immunohistochemistry + CD8 + T cell ratio.
As can be seen from the tumor growth curves of fig. 5A and 5B, knockout LINC02096 significantly inhibited tumor growth in esophageal squamous carcinoma, combined with PD-1 mab tumor growth in esophageal squamous carcinoma was further inhibited.
It can be seen from fig. 5B, 5C, and 5D that knockout of LINC02096 significantly increases CD8 + T cells and IFN-gamma + CD8 + T or GranB + CD8 + T cell ratio, combined PD-1 mab CD8 + T cells, IFN-gamma + CD8 + T or GranB + CD8 + The proportion of T cells becomes further large. The result shows that the LINC02096 can be knocked out to obviously increase CD8 + Infiltration of T cells in tumors and activity of the T cells to kill tumors further illustrate that LINC02096 participates in immune escape of esophageal squamous carcinoma by inhibiting T cell killing tumors. The LINC 02096-targeted therapeutic means and the anticancer mode of combined immunotherapy have anticancer prospect.
Example 5 specific nucleic acid drug targeting LINC02096 and anticancer Effect of Combined immunotherapy on esophageal squamous carcinoma
1. Experimental grouping
A. Control group: non-specific ASO sequence control inhibitor+igg;
B. PD-1 mab experimental group: non-specific ASO sequence control inhibitor+pd-1 mab;
C. LINC02096-inhibitor experiment group: specific nucleic acid drug ASO+IgG targeting LINC 02096;
D. LINC02096-inhibitor combined PD-1 mab experimental group: specific nucleic acid drug ASO+PD-1 monoclonal antibody targeting LINC02096.
2. Experimental method
1. Construction of a specific nucleic acid drug targeting LINC 02096:
designing and screening a specific nucleic acid drug ASO (LINC 02096-inhibitor) for targeted inhibition of LINC02096, and packaging into an exosome to obtain the LINC02096-inhibitor nucleic acid drug.
The specific nucleic acid drug ASO sequence of the targeted LINC02096 is shown in SEQ ID NO.11, and specifically comprises the following steps: 5'-AGCGCACCGAAAGGAACCAA-3'.
ASO (Antisense oligonucleotide) is antisense oligonucleotide, and after special chemical modification, the ASO can play an effective lncRNA inhibition role in an in-vivo model.
The non-specific ASO sequence control inhibitor is a disordered non-specific nucleotide sequence.
2. Construction of humanized-humanized tumor tissue graft (PDX) model
S1, constructing a PDX model, cutting esophageal squamous carcinoma tumor tissues from a patient into proper volumes, and immediately inoculating the esophageal squamous carcinoma tumor tissues into the subcutaneous of a NOG immunodeficiency mouse.
S2, when the successfully established PDX (P1) reaches about 500mm 3 At this time, mice were sacrificed, tumors were cut into appropriate volumes, transplanted onto a second batch of mice (P2), the procedure was repeated, and tumor tissue was transplanted onto a third batch of mice (P3), resulting in mice with P3 grafts.
S3, finally, the PBMC of the healthy volunteers are transplanted by tail vein injection by using the mice with the P3 implant, wherein the injection amount is 1 multiplied by 10 7 Construction of an immune System humanized mouse model (huPBMC-NOG-PDX)
3. Animal experiment
The corresponding treatments are respectively given according to the above groups: igG and PD-1 antibody were administered 1 time every 3 days at a dose of 200 μg/mouse by intraperitoneal injection for 3 total treatments; the effect on PDX tumor growth was observed in a humanized-human tumor tissue graft (PDX) model by tail vein injection of a specific nucleic acid drug ASO targeting LINC02096 or a non-specific ASO sequence control inhibitor, injected once every 3 days, 10nmol each time. Tumor volume and mouse body weight were measured every 3 days when tumor volume of any mouse reached 2000mm 3 At the same time, all the test mice are euthanized by cervical dislocation, the tumor volumes are counted, and the treatment effect differences among different treatment groups are compared.
The proportion of each immunocyte subset in the tumor was detected by flow cytometry, and the experimental method was the same as in example 3.
3. Experimental results
The experimental results are shown in fig. 6, and as can be seen from fig. 6, LINC02096-inhibitor can obviously inhibit the growth of tumors in esophageal squamous carcinoma bodies, and PD-1 monoclonal antibody can further inhibit the growth of tumors in bodies; LINC02096-inhibitor can increase CD8 + T cells and IFN-gamma + CD8 + T cell ratio, combined PD-1 mab CD8 + T cells and IFN-gamma + CD8 + The proportion of the T cells is further increased, which indicates that LINC02096-inhibitor can increase the activity of killing tumor by the T cells, LINC02096-inhibitor has obvious anticancer effect, and LINC02096-inhibitor can improve the anticancer effect of PD-1 monoclonal antibody.
The above examples are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above examples, and any other changes, modifications, substitutions, combinations, and simplifications that do not depart from the spirit and principle of the present invention should be made in the equivalent manner, and the embodiments are included in the protection scope of the present invention.
Claims (10)
- Use of linc02096 for predicting the effect and/or prognosis of an esophageal cancer immunotherapy.
- Use of linc02096 as a marker for predicting the effect and/or prognosis of an esophageal cancer immunotherapy.
- 3. Application of a reagent for detecting LINC02096 in preparing a kit for predicting the immunotherapy effect and/or prognosis of esophageal cancer.
- Use of linc02096 as a target for esophageal cancer therapy.
- Use of an inhibitor of linc02096 in the manufacture of a medicament for the treatment of esophageal cancer.
- Application of LINC02096 inhibitor in preparing synergist of esophageal cancer immunotherapy drug is provided.
- Use of an inhibitor of linc02096 in combination with a PD-1 antibody for the preparation of a medicament for the treatment of esophageal cancer.
- 8. A medicament for treating esophageal cancer, comprising an inhibitor of LINC02096.
- 9. The medicament of claim 8, further comprising a PD-1 antibody.
- 10. A kit for predicting the effect and/or prognosis of an immunotherapy of esophageal cancer, comprising a reagent for detecting LINC02096.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310162695.2A CN116676385B (en) | 2023-02-22 | 2023-02-22 | Application of LINC02096 in serving as marker for predicting esophageal cancer immunotherapy effect and prognosis and treatment target |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310162695.2A CN116676385B (en) | 2023-02-22 | 2023-02-22 | Application of LINC02096 in serving as marker for predicting esophageal cancer immunotherapy effect and prognosis and treatment target |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116676385A true CN116676385A (en) | 2023-09-01 |
| CN116676385B CN116676385B (en) | 2023-12-08 |
Family
ID=87781528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310162695.2A Active CN116676385B (en) | 2023-02-22 | 2023-02-22 | Application of LINC02096 in serving as marker for predicting esophageal cancer immunotherapy effect and prognosis and treatment target |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116676385B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108588220A (en) * | 2018-04-26 | 2018-09-28 | 汕头大学医学院附属肿瘤医院 | Esophageal squamous cell carcinoma long-chain non-coding RNA LINC01419 molecular markers and its application |
| CN109735620A (en) * | 2019-01-10 | 2019-05-10 | 中山大学肿瘤防治中心 | A kind of application of molecular target in esophageal squamous cell carcinoma prognosis evaluation and treatment |
| CN111172283A (en) * | 2020-02-18 | 2020-05-19 | 东南大学 | Application of detecting linc00673 expression quantity in esophageal cancer targeted therapy prognosis evaluation kit |
| CN111714629A (en) * | 2020-05-13 | 2020-09-29 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Application of medicine composition in preparing medicine for treating tumor insensitive to PD-1 antibody immunotherapy |
| CN111763740A (en) * | 2020-08-13 | 2020-10-13 | 中国医学科学院肿瘤医院 | System for predicting treatment effect and prognosis of neoadjuvant radiotherapy and chemotherapy of esophageal squamous carcinoma patient based on lncRNA molecular model |
-
2023
- 2023-02-22 CN CN202310162695.2A patent/CN116676385B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108588220A (en) * | 2018-04-26 | 2018-09-28 | 汕头大学医学院附属肿瘤医院 | Esophageal squamous cell carcinoma long-chain non-coding RNA LINC01419 molecular markers and its application |
| CN109735620A (en) * | 2019-01-10 | 2019-05-10 | 中山大学肿瘤防治中心 | A kind of application of molecular target in esophageal squamous cell carcinoma prognosis evaluation and treatment |
| CN111172283A (en) * | 2020-02-18 | 2020-05-19 | 东南大学 | Application of detecting linc00673 expression quantity in esophageal cancer targeted therapy prognosis evaluation kit |
| CN111714629A (en) * | 2020-05-13 | 2020-09-29 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Application of medicine composition in preparing medicine for treating tumor insensitive to PD-1 antibody immunotherapy |
| CN111763740A (en) * | 2020-08-13 | 2020-10-13 | 中国医学科学院肿瘤医院 | System for predicting treatment effect and prognosis of neoadjuvant radiotherapy and chemotherapy of esophageal squamous carcinoma patient based on lncRNA molecular model |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116676385B (en) | 2023-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020200114B2 (en) | Methods and assays relating to circulating tumor cells | |
| Huang et al. | lncRNA MALAT1 binds chromatin remodeling subunit BRG1 to epigenetically promote inflammation-related hepatocellular carcinoma progression | |
| Cao et al. | The long intergenic noncoding RNA UFC1, a target of MicroRNA 34a, interacts with the mRNA stabilizing protein HuR to increase levels of β-catenin in HCC cells | |
| Wang et al. | FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner | |
| US20210301349A1 (en) | Compositions and methods for treating a tumor suppressor deficient cancer | |
| KR20230170142A (en) | Treating metastatic cancer and model systems for metastatic disease | |
| Zhang et al. | Overexpression of LncRNA BM466146 predicts better prognosis of breast cancer | |
| Wang et al. | Circular RNA CircPPP1CB suppresses tumorigenesis by interacting with the MiR-1307-3p/SMG1 axis in human bladder cancer | |
| CN111020032A (en) | Application of miRNA-196b as non-small cell lung cancer molecular marker and therapeutic target | |
| Li et al. | A novel circular RNA CircRFX3 serves as a sponge for MicroRNA-587 in promoting glioblastoma progression via regulating PDIA3 | |
| Huang et al. | The β-catenin-LINC00183-miR-371b-5p-Smad2/LEF1 axis promotes adult T-cell lymphoblastic lymphoma progression and chemoresistance | |
| CN116676385B (en) | Application of LINC02096 in serving as marker for predicting esophageal cancer immunotherapy effect and prognosis and treatment target | |
| CN114045336B (en) | Application of CGA gene as target spot in preparation of medicine for diagnosing and treating drug-resistant solid tumor | |
| Long et al. | Intergenic CircRNA Circ_0007379 Inhibits Colorectal Cancer Progression by Modulating miR-320a Biogenesis in a KSRP-Dependent Manner | |
| Mei et al. | CircADARB1 serves as a new biomarker in natural killer T-cell lymphoma and a potential regulator of p-Stat3 | |
| WO2019031637A1 (en) | Cancer marker genes for p53-non mutational cancer, and therapeutic agent screening method | |
| Shi et al. | Long intergenic non‐coding RNA 00337 confers progression of esophageal cancer by mediating microrna‐145‐dependent fscn1 | |
| US20220016205A1 (en) | Methods of overcoming resistance to immune checkpoint inhibitors | |
| Zhu et al. | Plasmacytoma variant translocation 1 inhibits miR‐515‐5p function and modulates high mobility group B3 to promote the growth of prostate cancer cells | |
| Kang et al. | CPSF1 positively regulates NSDHL by alternative polyadenylation and promotes gastric cancer progression | |
| Sun et al. | Circ_0005231 promotes the progression of esophageal squamous cell carcinoma via sponging miR‐383‐5p and regulating KIAA0101 | |
| CN111518900A (en) | Application of miR-1246 as marker for diagnosing and treating acute myeloid leukemia | |
| CN115247213B (en) | Application of long-chain non-coding RNA LINC00205 in preparation of medicines for diagnosing or treating colorectal cancer | |
| CN114790457B (en) | Application of circB3GALNT2 in colorectal cancer metastasis prediction and treatment product | |
| Xu et al. | CircRNA_0000392 Promotes Colorectal Cancer Progression by Sponging miR-193a-5p |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |